stockrowTransMedics Group, Inc.
TMDX Healthcare Medical Devices
TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −31.0%
- Free cash flow
- −55.4%
- Total debt
- −89.3%
Quarter to September 2026, against a year earlier
Follow TMDX
Alert me
TransMedics Group, Inc. (TMDX) EBITDA
TransMedics Group, Inc.'s EBITDA for fiscal 2025 was $135.8M, up 137.1% from $57.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was $126.9M. Over the past ten years it has ranged from −$37.6M (fiscal 2021) to $135.8M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 4 consecutive fiscal years. TransMedics Group, Inc. ranks 25th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $135.8M | 137.13% |
| FY2024 | $57.3M | — |
| FY2023 | −$20.6M | — |
| FY2022 | −$28.0M | — |
| FY2021 | −$37.6M | — |
| FY2020 | −$24.8M | — |
| FY2019 | −$28.4M | — |
| FY2018 | −$19.5M | — |
| FY2017 | −$19.8M | — |
| FY2016 | −$22.6M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $39.0M | 14.72% |
| Jun 2026 | $34.0M | 35.04% |
| Mar 2026 | $25.2M | (12.46%) |
| Dec 2025 | $28.7M | (4.67%) |
| 31 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| TMDX TransMedics Group, Inc. | $126.9M |
| NEOG Neogen Corporation compare | $116.5M |
| UFPT UFP Technologies, Inc. compare | $116.0M |
| INSP Inspire Medical Systems, Inc. compare | $33.2M |
| AXGN AxoGen, Inc. compare | −$4.1M |
| ESTA Establishment Labs Holdings Inc. compare | −$8.1M |
| ALMR Alamar Biosciences, Inc. compare | −$38.4M |
| BFLY Butterfly Network, Inc. compare | −$51.0M |
| NVCR NovoCure Limited compare | −$119.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on TMDX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement